NEPRO: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of NEPRO. The page also collects GeneMedi's different modalities and formats products for NEPRO in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the NEPRO target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Introcelluar Protein.

Predicted to be involved in negative regulation of neuron differentiation and positive regulation of Notch signaling pathway. Predicted to be located in nucleolus. Predicted to be active in nucleus. Implicated in anauxetic dysplasia 3. [provided by Alliance of Genome Resources, Apr 2022]

Pre-made anti-NEPRO inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-NEPRO monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-NEPRO mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Recombinant multi-species NEPRO/ C3orf17/ NET17 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine NEPRO protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.